Resources

Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development

SAN MATEO, Calif., (March 5, 2026) – Helix, the leading enterprise genomics company, today announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provi

Helix Partners with Mawi DNA Technologies to Expand Access to Non-Invasive Genomic Sample Collection

Buccal swab technology complements existing collection approaches, enabling broader participation in population genomics

Advancing Genomics and Precision Medicine: Helix's Innovative Approach Earns 2026 BIG Innovation Award

2026 BIG Innovation Awards: 159 Trailblazers Prove WhereInnovation Is ReallyHappening

Performance and Applications of Helix’s Exome+® Assay

Helix’s Exome+® assay is run on all samples sequenced at Helix. This single assay combines a clinical exome with uniform panel-grade tests, a genome-wide backbone, and full mitochondrial coverage. P

Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia

From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence

What's with RWE? Sequencing Your Genome is Inevitable: A Conversation with Dr. James Lu

Unlocking Precision Medicine Through Curated Clinico-Genomic Data: A MASH Case Study

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is becoming a leading cause of liver dysfunction, affecting over 20 million Americans. However, identifying at-risk patients and studying dise

Hypercholesterolemia polygenic score modulates response to statin therapy

Unlocking the Genetic Key to Statin Effectiveness

Better Data, Better Diagnoses: The Power of Shared Genomic Data

Genetic test results are only as reliable as the data behind them. That's why collaboration across the industry matters, inspiring a collective effort toward accurate diagnoses and better patient outc

How Record Q4 2025 Growth in GenoSphere Clinico-genomic Cohorts Is Advancing Precision Medicine Research

Key Highlights GenoSphere™ is Helix's centralized clinico-genomic research data ecosystem — with specialized cohorts that combine whole Exome+® sequencing data linked to an average of 13 years of lon

Partnering with Veracyte to Deliver More Complete Genomic Insights in Prostate Cancer Care

Helix and Veracyte collaborate to expand access to combined germline and tumor transcriptomic testing through an integrated clinical workflow